GlassScriptPhysician profile
Susan C Moore
NPI 1689682049
$1,575.32
in general payments reported to CMS, 2019-2025
19 companies · $354 in 2025
The $354 reported for 2025 was more than what a typical Adult Health (Clinical Nurse Specialist) provider received nationally (typical 2025 total: $186).
See the full distribution for Adult Health (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.57 · 2022: $348 · 2023: $424 · 2024: $425 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,103 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,102.77 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $783.03 | 2022-2025 | |
| Incyte Corporation | $201.83 | 2022-2025 | Jakafi, Niktimvo |
| Merck Sharp & Dohme LLC | $62.83 | 2023 | Keytruda, Lynparza, Welireg |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.98 | 2024-2025 | Caplyta |
| Abbvie INC. | $58.93 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $57.31 | 2022-2023 | Tagrisso |
| Bayer Healthcare Pharmaceuticals INC. | $49.00 | 2022-2023 | |
| Genentech USA, INC. | $40.33 | 2021-2023 | Avastin, Rozlytrek, Alecensa |
| Genzyme Corporation | $38.28 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $37.66 | 2022-2023 | Imbruvica |
| Tersera Therapeutics LLC | $31.01 | 2022 | |
| Seagen INC. | $26.71 | 2022-2023 | Tivdak |
| Dexcom, INC. | $24.99 | 2024 | Dexcom G6 Transmitter |
| Sobi, INC | $23.23 | 2023 | |
| Taiho Oncology, INC. | $22.31 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $19.82 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $15.77 | 2022 | |
| Eisai INC. | $14.07 | 2023 | |
| Rigel Pharmaceuticals, INC. | $6.23 | 2023 | Rezlidhia, Tavalisse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.